as your sales would has as CFO, more move company’s am a and growing Fred as Officer. everyone details years, Chief And Monaco and before to here our Erica that we with part from like today. interest on Tirth us Biofrontera. – to of team I Biofrontera’s the thanks X IPO Director company resigned and to you, our inform CEO. I been then starting Thank of in Yes. for the company Leffler. to performance, Finance you We Erica appreciate has on Operations together joining Financial
the since. I Following Chairman future to to great Erica CEO wish in from held back the IPO, We go and I building of become this stepped her led thank to all had as Executive for contribution her CEO, the endeavors. company and Biofrontera role Erica which best
of market. As Executive stock to ensure responsibilities Chairman, on maintain confidence the the core am uninterrupted signal we the I business priorities over taking our and focus CEO to
plans and term. force of forward including sales of and With areas, are reviewing drive goals our our all sales start forward. I’m long that, expanding and teams strong look proud for our the that and several will I progress maturation a expansion Ameluz going across growth to supporting studies. Today, factors of label number both year our to There our of Ameluz discuss our near the use, these I’ll execution.
Let revenues. revenues me XXXX million. begin QX with quarter were $X.X Total for first
so April effect. we increase. experience results year similar XXXX, have such year, price increase We the buy-in prior a didn’t customer did X, publicized buy-in of were Our by price this ahead boosted not a
year-over-year As comparison actual is a a very the strength. business result, useful indicator of not
a historically of significant in was In very fact, XXXX QX way. strong
It quarter – best than with the the which in it higher buy XX% the increase. in at volume excluding had quarter, the we did that profit before from first was highest was, a last Looking quarter, first QX boost. company’s first year’s price fact, the not history, and
the in Miami in spring including market Beach. treatment continued of education Winter we requires Palm meeting Maui AOCD quarter, the several and of attended Clinical, with demand end, actinic the for Derm, Ameluz-PDT on To products. keratosis conferences West our Driving the that industry the first
year’s the the at presence Annual initiatives. awareness Meeting, prestigious dermatology and is largest critical We also significant education sustaining Improving a to have Academy medical most American brand conference. Dermatology of
So these and with held and many met booth. live potential partners current demonstrations customers and conferences, we while attending at our
As is can to spent a where high most maximize carefully events are impactful visibility and where lean best we evaluate prioritize our sales we time organization, leads.
driver quarter nurture of customer customers. was sales Another and our gold and sales reach success experience to the size in and takes key building of relationship continue gain is the especially is maturation and enables customer important broader deliver see force relationships and to encouraging as deeper Maturation It they force. improve while the as our board. education among across time,
growing We have significant investment our in force. sales made a
we strategy, of our and us the encompassing brand in region adoption sales. enables expansion larger force XX to sales dermatologists cultivate now consequently, coverage increased higher sales relationships nearly meaningful As This XX% part result added heightened that with a number with the new and broader awareness, of by reps territories.
the sales accelerating to quarter, force this our as newer Following our national meeting past the equipped more execute and continue a reps ones on tenured productive and to goals I to deliver begin ramp. see collective
the the trunk Ameluz potential are studies sufficiently PDT our another Ameluz several patient Phase on and path X use extremities, expansions extension and the in makes label enrolled. label new opportunities evaluating large and While market evaluating label was Ameluz the for of our neck accessible the AK us. track the in of expectations Earlier the growth year, study current near-term, clinical to for market indications. of first part maximize Every this supports to a
of stratified clinical trial, been which at initiated XXX to has patients in Meanwhile, speedily screening patients With XX the body centers actinic are dosed now a patients scalp. a aim a and therapy effective and by growing is XX AK highly have XX million and very driving large region. XX centers enroll Americans keratosis to XX demand there an approximately face the treat annually, for and million treatments beyond total estimated affecting
keratosis both treat providers per enabling using last patient treated X surface study approval and FDA of visits effective recently the fewer Actinic treatments planned requiring physicians office study, the for the tubes and an report tubes in multicenter be to This treatment. Phase benefits tolerability three-tube safety addition, patient. QX. been area three by treatment safety for open-label In of has wider has potentially and study three required study for investigating the Ameluz FDA the in is submission potential to a final patients
outcomes Following other these of significantly to updates year. label revenue. opportunities the studies, this to more We significantly later potential position successful create and competitive providing and expansions our look forward can drive improve
as prioritizing continuum We areas dermatologists treatment for therapy and interest to along non-melanoma treat. well the portfolio conditions that evaluate for of also expansion, our continue as of skin additional cancer diagnosis, post opportunities
expect a portfolio to to type current of we be While our a diversified future growth on are important our currently we plans. focused scaling assets,
company gets matters. into Fred results would Before address like of I and in our financial couple a detail, details to additional
holding split. a special to XX. on We this reverse a May will vote purpose meeting stockholders of effect The meeting stock is of be the proposal on to
common price of Biofrontera’s earlier we a the – of year, our Given received from letter stock non-compliance this NASDAQ. the
share for reverse to minimum to in compliance The the stock our this continued per is split of price attend order stock listing. bid of to the increase requirement proposal regain with
for a of in We make split encourage reverse more all to the split company We interest is vote our and reverse to the it attractive also stock believe believe range investors. stock and broader shareholders. best common the will of stock shareholders the all
requirements. of strengthen seasonal tend have first a most reduce cash will purchasing the capital we during credit to fourth and customer when now steps position. to We are our quarters have address the help inventory taking line help This drawdowns also to demand. We
and were while I by the start revenues summarize, down year-over-year historic year, showed past of the our very are this am the positive tough quarter. comparison, trends strength encouraged to due to So volume
We a sales grow revenues by remain on XX% track year or primarily more to driven revenue Ameluz force. by and maturing this
reach to accelerate execute we the growth. discipline, confident and to necessary X given that flexibility remain years. expect the have And sales next to financial expectations cash flow make we within and the breakeven We our will financial investments
With turn details Fred the to over the quarter. of the that, walk to financial I’ll through call
